On ECHEMI
Home > Drugs > Yaopharma Co., Ltd.

Yaopharma Co., Ltd.

  • Founded in:

    1997-07-21
  • Country:

    China China
  • Address:

    No. 100, Xingguang Avenue, Renhe Town, Yubei District, Chongqing
  • Tax NO.:

    91500000202851807X
  • Registered Funds:

    196.54 million yuan
  • Website:

  • Email:

Related Drugs
Fat emulsion injection
This product is a sterile emulsion made of soybean oil for injection, emulsified with lecithin for injection and added with glycerin for injection. Each 1000ml contains: 10% 20% 30% soybean oil for injection 100g 200g 300g lecithin for injection 12g 12g 12g glycerin for injection 22g 22g 16.7g water for injection (add to) 1000ml 1000ml 1000ml pH value is about 888 Osmotic pressure (mosm/kgH2O) 300 350 310 Energy/MJ (kcal) 4.6 (1100) 8.4 (2000) 12.6 (3000)
Name Description Content CAS NO. Registered Holders
Soybean oil

100g/200g/300gg 8001-22-7 25
Egg phospholipids

12gg 93685-90-6 26
Glycerol

22g/22g/16.7gg 56-81-5 62
Fasudil Hydrochloride
Name Description Content CAS NO. Registered Holders
Fasudil hydrochloride

105628-07-7 54
Huperzine A Capsules
The main ingredient of this product: Huperzine A.
Name Description Content CAS NO. Registered Holders
(-)-Huperzine A

This product is a cholinesterase (ACHE) inhibitor, which has a selective inhibitory effect on acetylcholinesterase (ACHE) and can easily pass through the blood and cerebrospinal fluid barriers. It has the effect of promoting memory reproduction and enhancing memory retention.

More

This product is a cholinesterase (ACHE) inhibitor, which has a selective inhibitory effect on acetylcholinesterase (ACHE) and can easily pass through the blood and cerebrospinal fluid barriers. It has the effect of promoting memory reproduction and enhancing memory retention.

102518-79-6 7
Lamivudine Tablets
The main ingredient of this product is lamivudine
Name Description Content CAS NO. Registered Holders
Lamivudine

Lamivudine is a nucleoside antiviral drug. It has a strong inhibitory effect on hepatitis B virus (HBV) in vitro and in experimentally infected animals. Lamivudine can be metabolized in HBV-infected cells and normal cells to produce lamivudine triphosphate, which is the active form of lamivudine and is both an inhibitor of HBV polymerase and a substrate of this polymerase. Lamivudine triphosphate penetrates into the viral DNA chain and blocks the synthesis of viral DNA. Lamivudine triphosphate does not interfere with the metabolism of deoxynucleosides in normal cells. It has a weak inhibitory effect on mammalian DNA polymerase a and b and has almost no effect on the DNA content of mammalian cells. Lamivudine has no obvious toxicity to the structure, DNA content and function of mitochondria. The results of serum HBVDNA detection in most hepatitis B patients showed that lamivudine can rapidly inhibit HBV replication, and its inhibitory effect lasts throughout the treatment process, while reducing serum aminotransferase to normal.

More

Lamivudine is a nucleoside antiviral drug. It has a strong inhibitory effect on hepatitis B virus (HBV) in vitro and in experimentally infected animals. Lamivudine can be metabolized in HBV-infected cells and normal cells to produce lamivudine triphosphate, which is the active form of lamivudine and is both an inhibitor of HBV polymerase and a substrate of this polymerase. Lamivudine triphosphate penetrates into the viral DNA chain and blocks the synthesis of viral DNA. Lamivudine triphosphate does not interfere with the metabolism of deoxynucleosides in normal cells. It has a weak inhibitory effect on mammalian DNA polymerase a and b and has almost no effect on the DNA content of mammalian cells. Lamivudine has no obvious toxicity to the structure, DNA content and function of mitochondria. The results of serum HBVDNA detection in most hepatitis B patients showed that lamivudine can rapidly inhibit HBV replication, and its inhibitory effect lasts throughout the treatment process, while reducing serum aminotransferase to normal.

134678-17-4 46
Methocarbamol Injection
Name Description Content CAS NO. Registered Holders
Methocarbamol

532-03-6 33
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.